Funding · Healthcare & Life Sciences

Mave Health raises $2.1 million seed round

By Startup Enthusiast · 19 March 2026

What they do

Mave Health makes a lightweight wearable headset that uses tDCS (transcranial direct current stimulation) to regulate focus, mood and stress

The company raised a $2.1 million seed round led by Blume Ventures, with participation from Inuka Capital, Stanford Angels and others

The headset weighs under 100 grams, requires 20 minutes daily use, and ships in April 2026 in the US and India

Mave Health raised $2.1 million (INR 18 crore) in a seed round led by Blume Ventures.
Participants included Inuka Capital, Stanford Angels, founders of Groww, Raymond Russell, Aureolis Ventures, Juhi Bhatnagar (Forj Capital), and Dhaval Shroff.
Existing investor All In Capital also doubled down in this round.
The company had previously raised a $750,000 pre-seed round in November 2023.
Total funding across both rounds is $2.82 million.
Funds will be used for launch in the US and India and to expand manufacturing capacity.
Shipping of the headset begins April 2026 in both countries.

The India healthtech wearables market is shifting from fitness tracking to advanced health monitoring and longevity.
Deepinder Goyal (ex-Eternal CEO) recently forayed into wearables with Temple, likely measuring brain blood flow.
Other startups in health-focused wearables include Sychedelic, Marbles Health, and InnerGize.
The India healthtech market is projected at $21.3 billion by 2025, growing at 27% CAGR, with over 5,200 startups.

Mave Health makes a lightweight wearable headset for focus, mood, and stress regulation using tDCS (transcranial direct current stimulation).
tDCS is a non-invasive brain stimulation technique studied for 25+ years with 10,000+ published studies, considered safe for at-home use.
The headset weighs under 100 grams and delivers low-intensity (1-2 mA) electrical current targeting the prefrontal cortex.
Users wear it for 20 minutes daily while working, reading, meditating, or doing routine tasks, with no learning curve.
Battery life lasts up to one month on a single charge with regular use.
A companion app lets users log sessions, personalize protocols, and track progress; no brain data is collected.
The headset is priced at $495 pre-order with no subscription fees.
Before public release, the company ran a beta programme with 500+ users.
Self-reported results after 4 weeks: 80% of users saw productivity improve >60%, 75% saw stress reduction >50%, and average mood improvement was 77%.

Blume Ventures (lead) — Venture capital firm; Arpit Agarwal is Investment Partner.
Inuka Capital (participant) — Investor in the round.
Stanford Angels (participant) — Angel investor group affiliated with Stanford University.
Groww founders (participant) — Founders of the investment platform Groww.
Raymond Russell (participant) — Individual investor.
Aureolis Ventures (participant) — Venture capital firm.
Juhi Bhatnagar (Forj Capital) (participant) — Investor through Forj Capital.
Dhaval Shroff (participant) — Individual investor.
All In Capital (existing) — Existing investor that doubled down in this round.
Bharat Founders Fund (participant) — Fund investing in Indian startups.

Product: Non-invasive wearable headsets using transcranial direct current stimulation (tDCS) for brain stimulation
Customers: Individuals seeking treatment for focus, mood, stress regulation and depression/anxiety
How it makes money: Direct-to-consumer hardware sales with clinical program subscriptions
What sets it apart: FDA-cleared technology using tDCS targeting prefrontal cortex; lightweight design (100g); clinically validated 68% recovery rate for depression
Operations: Manufacturing and fulfillment in US and India with clinical support infrastructure